4-Hydroxysesamin, a Modified Natural Compound, Attenuates Neuronal Apoptosis After Ischemic Stroke via Inhibiting MAPK Pathway
Lina Wang,Zhenzhen Qu,Qian Sun,Zhuofeng Mao,Peipei Si,Weiping Wang
DOI: https://doi.org/10.2147/ndt.s444760
IF: 2.989
2024-03-08
Neuropsychiatric Disease and Treatment
Abstract:Lina Wang, Zhenzhen Qu, Qian Sun, Zhuofeng Mao, Peipei Si, Weiping Wang Internal Medicine-Neurology, the Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China Correspondence: Weiping Wang, Internal Medicine-Neurology, the Second Hospital of Hebei Medical University, No. 215 Heping Road, Xinhua District, Shijiazhuang, 050004, People's Republic of China, Tel +86-13613316623, Email Background: The 4-hydroxysesamin (4-HS, a di-tetrahydrofuran lignin) is a modified sesamin that was prepared in the laboratory. This preclinical study was designed to preliminarily investigate the neuroprotective properties of 4-HS. Methods: In vitro, neuronal injury and inflammation were simulated by oxygen-glucose deprivation and lipopolysaccharide (LPS) exposure in mouse hippocampal neuronal HT22 cell line, and treated with 4-HS and/or metformin (MET, MAPK pathway activator for exploring mechanism). CCK-8, flow cytometry, and enzyme-linked immunosorbent assay were performed to evaluate cell viability, apoptosis, and inflammation. Apoptosis- and pathway-related proteins were detected by Western blotting. Middle cerebral artery occlusion (MCAO) was constructed as a stroke model and treated with 4-HS for in vivo confirmation. Histological staining was used for in vivo evaluation of 4-HS properties. Results: The 4-HS showed similar anti-inflammatory activity to sesamin but did not affect the cell viability of HT22 cells. In vitro, 4-HS improved the cell viability, ameliorated neuronal apoptosis, along with the reversion of apoptotic proteins (Bax, cleaved-caspase 3/9, Bcl-2) expression and inflammatory cytokines (IL-6, TNF-α, IL-10) in LPS-treated HT22 cells. The 4-HS suppressed the phosphorylation of ERK, JNK, and p38 but the addition of MET reversed 4-HS-induced changes of phenotype and protein expression in LPS-treated cells. In vivo, 4-HS showed apparent improvement in cerebral infarction, brain tissue morphology, neuronal architecture, apoptosis, and inflammation of MCAO mice, and also showed inhibiting effects on the phosphorylation of ERK, JNK, and p38, confirming in vivo results. Conclusion: In this first pre-clinical study on 4-HS, we preliminarily demonstrated the neuroprotective properties of 4-HS both in cell and animal models, and proposed that the underlying mechanism might be associated with the MAPK pathway. Keywords: sesamin, 4-hydroxysesamin, middle cerebral artery occlusion, ischemic stroke, neuronal apoptosis Stroke is the leading cause of long-term disability and affects about 15 million people each year, being a huge and increasing global health challenge. 1,2 Globally, ischemic stroke represents ~87% of total strokes 3 and currently has been the main concern in stroke research. 4 More critically, the global stroke burden continues to increase globally, especially in developing countries. 5,6 Despite the past decade has seen advances in treatment options, the available treatments for ischemic stroke are extremely limited. 7 Therefore, any alternative therapy likely to improve the outcome of stroke would be a valuable asset. Experimental findings have defined the pathogenic mechanisms involved in stroke injury, promoting the development of various agents that target the related injury pathways. 8 From the perspective of pathogenic mechanism, a complex series of pathophysiological events including apoptosis, oxidative stress, and inflammation contribute to cerebral injury after ischemic stroke. 9,10 Among them, apoptosis and inflammation, which occur in the penumbra, is currently one main targeting pathogenic process of most neuroprotective agents commonly used or in development. 8,11 Nevertheless, most neuroprotective agents failed to translate in clinical settings. 12 Sesamin, a furofuran lignan isolated from Sesamum indicum L . seeds., is known to possess anti-oxidant, anti-inflammatory, and neuroprotective properties. 13,14 As a potential natural therapeutic lignan, several in vitro and in vivo studies have illustrated its pharmacological activity in various diseases, such as ischemic brain stroke, 15 rheumatoid arthritis, 16 and breast cancer. 17 Recent clinical results have also demonstrated the anti-inflammatory properties of sesamin supplementation in rheumatoid arthritis, 18 type 2 diabetes. 19 However, until now, its application is still limited in clinical practice maybe due to low bioavailability and the limited level of activity. The 4-hydroxysesamin (4-HS, a di-tetrahydrofuran lignin) is a modified sesamin that was prepared in the laboratory. The pharmacological activity of 4-HS has not been explored widely. To date, num -Abstract Truncated-
psychiatry,clinical neurology